News
ASND
135.90
-0.75%
-1.03
Looking Into Ascendis Pharma's Recent Short Interest
Ascendis Pharma's short percent of float has risen 13.75% since its last report. The company has 3.35 million shares sold short. Short interest is the number of shares that have been sold short but have not yet been covered. Short selling is when a trader sells shares with the hope that the price will fall.
Benzinga · 12h ago
Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024
Ascendis Pharma A/S will report first quarter 2024 financial results and provide a business update on Thursday, May 2, 2024. The company will also host a conference call and live webcast to discuss its financial results. Ascendis Pharma will report its results after the close of the U.S. Financial markets.
Barchart · 1d ago
Ascendis Pharma Gains UK Authorization for YORVIPATH
TipRanks · 2d ago
Ascendis Pharma Says UK Approves YORVIPATH For Treatment Of Adults With Chronic Hypoparathyroidism
NASDAQ · 2d ago
Why Earnings Season Could Be Great for Ascendis Pharma (ASND)
NASDAQ · 2d ago
Ascendis Pharma Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 4d ago
Morgan Stanley Maintains Equal-Weight on Ascendis Pharma, Maintains $116 Price Target
Benzinga · 4d ago
Weekly Report: what happened at ASND last week (0415-0419)?
Weekly Report · 4d ago
$1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today
Ascendis Pharma has outperformed the market over the past 15 years by 17.87%. The company has an average annual return of 30.26%. If an investor bought $1000 of ASND stock 15 years ago, it would be worth $50,829.75 today.
Benzinga · 04/18 19:30
Ascendis Pharma Price Target Maintained With a $173.00/Share by Cantor Fitzgerald
Dow Jones · 04/18 13:53
Cantor Fitzgerald Reiterates Overweight on Ascendis Pharma, Maintains $173 Price Target
Benzinga · 04/18 13:43
Weekly Report: what happened at ASND last week (0408-0412)?
Weekly Report · 04/15 09:27
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amphastar Pharmaceuticals (AMPH), Ascendis Pharma (ASND) and AMN Healthcare Services (AMN)
TipRanks · 04/12 13:41
Ascendis Pharma A/S Outlines Financial Strategy
TipRanks · 04/11 08:37
Weekly Report: what happened at ASND last week (0401-0405)?
Weekly Report · 04/08 09:29
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
ProfoundBio, A Seattle-Suzhou ADC Biotech, will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. China Medical System in-licensed povorcitinib, an oral JAK1 inhibitor, for autoimmune and inflammatory dermatologic diseases. Shanghai's Visen Pharma announced plans to stage an IPO on the Hong Kong Exchange.
Seeking Alpha · 04/07 10:30
Some Confidence Is Lacking In Ascendis Pharma A/S' (NASDAQ:ASND) P/S
Ascendis Pharma A/S' price-to-sales ratio of 29.2x is higher than the Biotech industry average. The company's revenues are expected to grow by 65% over the next three years. However, the company's forecast growth is lower than the industry as a whole.
Simply Wall St · 04/05 11:40
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 44.46% on an annualized basis. Currently, Ascendis Pharma has a market capitalization of $8.28 billion. If an investor bought $100 of ASND stock 10 years ago, it would be worth $8,187.29 today.
Benzinga · 04/03 17:00
Ascendis Pharma Price Target Raised to $167.00/Share From $165.00 by JP Morgan
Dow Jones · 04/02 14:58
Ascendis Pharma Is Maintained at Overweight by JP Morgan
Dow Jones · 04/02 14:58
More
Webull provides a variety of real-time ASND stock news. You can receive the latest news about Ascendis Pharma through multiple platforms. This information may help you make smarter investment decisions.
About ASND
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).